Large differences in levodopa dose requirement in Parkinson's disease: Men use higher doses than women

European Journal of Neurology

Volumn 17, Issue 2, 2010, Pages 260-266

  Nyholm, D ^a   Karlsson, E ^a   Lundberg, M ^b   Askmark, H ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRE FOR EPIDEMIOLOGY   (Sweden)

Author keywords

Dose requirement; Gender; High dose; Levodopa; Parkinson's disease; Pharmacoepidemiology

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DYSKINESIA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; REGISTRIES; SEX FACTORS; SWEDEN; TIME FACTORS;

EID: 74549133445     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02866.x     Document Type: Article

References (27)

1. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977 1 : 345 349.
2. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999 246 : 1127 1133.
3. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008 15 : 493 496.
4. Kurlan R. "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005 64 : 923 924.
5. ATC/DDD index 2009 [database on the Internet]. http://www.whocc.no/ atcddd/ (accessed 04/06/2009).
6. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004 62 : 201 207.
7. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002 58 : 396 401. (Pubitemid 34150913)
8. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ, et al. Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry 2005 76 : 34 39.
9. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007 29 : 1825 1849.
10. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997 62 : 10 15.
11. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000 54 : S21 S23.
12. Ekbom K. Restless legs: a clinical study. Acta Med Scand 1945 158 (Suppl 1 123.
13. Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology 1999 52 : 907 910. (Pubitemid 29161595)
14. Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007 22 (Suppl. 18 S466 S475.
15. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996 19 : 205 213.
16. Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 2006 21 : 1221 1225.
17. Menniti-Ippolito F, Spila-Alegiani S, Vanacore N, et al. Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Acta Neurol Scand 1995 92 : 49 54.
18. Paus S, Grunewald A, Klein C, et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov Disord 2008 23 : 599 602.
19. Muller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000 6 : 171 173.
20. Murata M, Mizusawa H, Yamanouchi H, Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996 103 : 1177 1185.
21. Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Muller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004 363 : 284 287.
22. Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989 28 : 61 69.
23. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991 41 : 463 466.
24. Kompoliti K, Adler CH, Raman R, et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002 58 : 1418 1422.
25. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 2003 24 : 192 193.
26. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007 78 : 819 824.
27. Horstink MW, Haaxma C, Bloem BR. About the anti-Parkinson equivalency of levodopa and dopamine agonists. Clin Neuropharmacol 2007 30 : 60 62.